CN112543636B - 治疗与egfr突变相关的癌症的组合物和方法 - Google Patents

治疗与egfr突变相关的癌症的组合物和方法 Download PDF

Info

Publication number
CN112543636B
CN112543636B CN201980050963.3A CN201980050963A CN112543636B CN 112543636 B CN112543636 B CN 112543636B CN 201980050963 A CN201980050963 A CN 201980050963A CN 112543636 B CN112543636 B CN 112543636B
Authority
CN
China
Prior art keywords
plinabulin
tumor
administered
cancer
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980050963.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN112543636A (zh
Inventor
黄岚
乔治·肯尼斯·劳埃德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeyondSpring Pharmaceuticals Inc
Original Assignee
BeyondSpring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BeyondSpring Pharmaceuticals Inc filed Critical BeyondSpring Pharmaceuticals Inc
Publication of CN112543636A publication Critical patent/CN112543636A/zh
Application granted granted Critical
Publication of CN112543636B publication Critical patent/CN112543636B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201980050963.3A 2018-06-01 2019-05-30 治疗与egfr突变相关的癌症的组合物和方法 Active CN112543636B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862679619P 2018-06-01 2018-06-01
US62/679,619 2018-06-01
PCT/US2019/034726 WO2019232257A1 (en) 2018-06-01 2019-05-30 Composition and method of treating cancer associated with egfr mutation

Publications (2)

Publication Number Publication Date
CN112543636A CN112543636A (zh) 2021-03-23
CN112543636B true CN112543636B (zh) 2024-03-01

Family

ID=68696755

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980050963.3A Active CN112543636B (zh) 2018-06-01 2019-05-30 治疗与egfr突变相关的癌症的组合物和方法

Country Status (11)

Country Link
US (2) US20210161888A1 (https=)
EP (1) EP3801524B1 (https=)
JP (1) JP7500438B2 (https=)
KR (1) KR102790127B1 (https=)
CN (1) CN112543636B (https=)
AU (1) AU2019278886B2 (https=)
CA (1) CA3101612A1 (https=)
DK (1) DK3801524T3 (https=)
ES (1) ES3060133T3 (https=)
MX (1) MX420412B (https=)
WO (1) WO2019232257A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383691B (es) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
WO2017139231A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
RU2760348C2 (ru) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Способ уменьшения нейтропении
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
AU2022357570A1 (en) * 2021-10-03 2024-04-11 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof
CN117860672A (zh) * 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
EP4719416A1 (en) * 2023-06-02 2026-04-08 Beyondspring Pharmaceuticals, Inc. Oncology combination therapy and methods of use
CN120682197A (zh) * 2024-03-19 2025-09-23 大连万春布林医药有限公司 普那布林的盐晶型

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054498A2 (en) * 2002-08-02 2004-07-01 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
CN105358576A (zh) * 2013-02-20 2016-02-24 诺华股份有限公司 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
CN107530341A (zh) * 2015-03-06 2018-01-02 万春药业公司 治疗与ras突变相关的癌症的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer
US20110160159A1 (en) * 2009-09-15 2011-06-30 John Ryan Treatment of cancer
AU2016219204B2 (en) * 2015-02-12 2021-01-21 Beyondspring Pharmaceuticals, Inc. Use of Plinabulin in combination with immune checkpoint inhibitors
AU2018236168B2 (en) * 2017-03-13 2024-02-29 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054498A2 (en) * 2002-08-02 2004-07-01 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
CN105358576A (zh) * 2013-02-20 2016-02-24 诺华股份有限公司 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
CN107530341A (zh) * 2015-03-06 2018-01-02 万春药业公司 治疗与ras突变相关的癌症的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non–Small-Cell Lung Cancer";Ramalingam S S, etal.;《Journal of Clinical Oncology》;第36卷(第9期);第841-849页 *
"The KRAS Mutation is Highly Correlated With EGFR Alterations in Patients With Non-small Cell Lung Cancer";YANG.MING-JE., etal.;《 Fooyin J Health Sci》;第1卷(第2期);第65-71页 *

Also Published As

Publication number Publication date
DK3801524T3 (da) 2026-02-02
US20250375440A1 (en) 2025-12-11
US20210161888A1 (en) 2021-06-03
KR102790127B1 (ko) 2025-04-03
JP2021525768A (ja) 2021-09-27
EP3801524A1 (en) 2021-04-14
MX420412B (es) 2025-02-10
JP7500438B2 (ja) 2024-06-17
CA3101612A1 (en) 2019-12-05
CN112543636A (zh) 2021-03-23
EP3801524B1 (en) 2025-11-05
KR20210015875A (ko) 2021-02-10
AU2019278886B2 (en) 2025-03-20
AU2019278886A1 (en) 2020-12-24
WO2019232257A1 (en) 2019-12-05
MX2020012799A (es) 2021-03-25
ES3060133T3 (en) 2026-03-25
EP3801524A4 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
CN112543636B (zh) 治疗与egfr突变相关的癌症的组合物和方法
US12343344B2 (en) Pharmaceutical combination comprising TNO155 and ribociclib
US9216170B2 (en) Combination therapy for proliferative disorders
CN103458690B (zh) 治疗肺动脉高压的组合物和方法
KR20170131491A (ko) Ras 돌연변이와 관련된 암의 치료 방법
US20160129003A1 (en) Pharmaceutical Combinations
US9750739B2 (en) Orvepitant for chronic cough therapy
US20250041277A1 (en) Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
US20220031657A1 (en) Pharmaceutical combination comprising lsz102 and ribociclib
US12090153B2 (en) Combination therapy for the treatment of uveal melanoma
HK40038993A (en) Composition and method of treating cancer associated with egfr mutation
US20080312250A1 (en) Combination Comprising a Bcrp Inhibitor and 4- (4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl] -Benzamide
RU2849370C1 (ru) Способы и схемы дозирования, содержащие ингибитор cdk2 и ингибитор cdk4, для лечения рака
CN121311228A (zh) 肿瘤联合治疗和使用方法
HK40116611A (zh) 用於治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40038993

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant